

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9516-039-999

APPLICATION NO.

09/704,054

APPLICANT

D'AMATO

FILING DATE

November 1, 2000

ART UNIT

1614

U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C309 Avalos-Diaz, et al., "Inhibitory Effect on Endocytosis in Polymorphonuclear Cells Caused by Thalidomide", Arch. Invest. Med., vol. 16, No. 2, pp. 139-143 (1985)	
	C310 Dhodapkar, et al., "A Phase II Pilot Study of Anti-Angiogenesis Therapy Using Thalidomide in Patients with Multiple Myeloma", UARK 98-003, pp. 1-15 (1998)	
	C311 Gaetani, M., "Studi Sull'Attivita Antitumorale Della Thalidomide", Giornale Italiano diu Chemioterapia, pp. 83-86 (1964)	
	C312 Kenyon, et al., "The Discovery of New Inhibitors of Angiogenesis Using an Improved Mouse Corneal Neovascularization Model", No. 459-367, p. S94 (Abstract only) (1994)	
	C313 Neubert, "Teratogenicity: Any Relationship to Carcinogenicity?", Institute for Toxicology and Embryopharmacology, Free University of Berlin, Berlin, Federal Rep. Of Germany, pp. 169-178 (1979)	
	C314 Peyron, et al., "The Pharmacological Basis for the Treatment of Photodermatoses", Biochimie, vol. 68, No. 6, pp. 899-904 (1986)	
	C315 Proenca, N.G., "Thalidomide: An Eclectic Medication in Dermatology", Rev. Paul. Med., vol. 107, No. 1, pp. 41-46 (1989)	
	C316 Smith, et al., "Studies on the Relationship Between the Chemical Structure and Embryotoxic Activity of Thalidomide and Related Compounds", Chemical Structure and Embryopathy, pp. 194-209 (1965)	
	C317 Wesolowski, et al., "Effect of Light on a Murine Model of Retinopathy of Prematurity", Invest. Opthamol. & Visual Science, vol. 33, No. 4, p. 1281 (Abstract only) (1992)	

NYI-4070772v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 9516-039-999	APPLICATION NO. 09/704,054
	APPLICANT D'AMATO	
	FILING DATE November 1, 2000	ART UNIT 1614

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C318	Furman, R.R., "Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabine-relapsed and refractory CLL", American Society of Clinical Oncology, May 2005, Abstract #6640	
	C319	Furman, Richard, et al., "Thalidomide is active alone and in combination with fludarabine in fludarabine-relapsed and refractory chronic lymphocytic leukemia", December 2004, Abstract #4835	
	C320	Furman, Richard, "Thalidomide With or Without Fludarabine in Treating Patients with Hematologic Cancer", ClinicalTrials.gov on December 31, 2007	
	C321	Steins, Martin, et al., "Efficacy and safety of thalidomide in patients with acute myeloid leukemia", Blood, February 2002, 99(3):834-839	
	C322	Steins, M.B., et al., "Thalidomide for the Treatment of Acute Myeloid Leukemia", Leukemia & Lymphoma, September 2003, 44(9):1489-1493	
	C323	Kreuter, Michael, et al., "Downregulation of neuropilin-1 in patients with acute myeloid leukemia treated with thalidomide", European Journal of Haematology, 2007, 79:392-397	
	C324	Strupp, C., et al., "Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide", Leukemia Research, 2005, 29:967-969	
	C325	Wöhrer, Stefan, et al., "Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone – a case report", The Hematology Journal, 2004, 5:361-363	
	C326	Ruan, Jia, et al., "Targeting angiogenesis in mantle cell lymphoma: Clinical efficacy and correlative studies of a phase II trial of RT-PEPC (rituximab, thalidomide and metronomic oral chemotherapy with prednisone, etoposide, procarbazine and cyclophosphamide) in relapsed/refractory disease)", American Society of Hematology, December 2006, Abstract #2751	
	C327	Damaj, G, et al., "Thalidomide therapy induces response in relapsed mantle cell lymphoma", Leukemia, 2003, 17:1914-1915	
	C328	Goy, Andre, "New Directions in the Treatment of Mantle Cell Lymphoma: An Overview", Clinical Lymphoma & Myeloma, October 2006, 7(Supp 1):S24-S32	
	C329	Game, Melaku, et al., "Thalidomide and low dose Vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's Disease (HD) and Non-Hodgkin's Lymphoma (NHL)", American Society of Hematology, December 2001, Abstract #5235	
	C330	Larson, Melissa, et al., "HIV-related Lymphoma Treated with Maintenance Thalidomide", Clinical Advances in Hematology & Oncology, March 2005, 3(3):231-235	
	C331	Ramasamy, Karthik, et al., "Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone", Haematologica, 2006, 91(1):117-118	
	C332	Folkman, Judah, "Angiogenesis: an organizing principle for drug discovery?", Nature Reviews, April 2007, 6:273-286	
	C333	Thomas, Deborah, et al., "Current role of thalidomide in cancer treatment," Current Opinion in Oncology, 2000, 12:564-573	
	C334	Brennen, W. Nathaniel, et al., "Thalidomide and Analogues: Current Proposed Mechanisms and Therapeutic Usage," Clinical Prostate Cancer, June 2004, 54-61	

NYI-4070772v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	